EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a regular round up of news relevant to hospital pharmacy in Europe.
You can subscribe to receive the EAHP EU Monitor by email HERE.
Organisations and individuals invited to register for common training framework consultationThe European Association of Hospital Pharmacists (EAHP) is inviting all interested organisations and individuals to register to participate in an online consultation on a common training framework (CTF) for hospital pharmacy.
A common training framework for hospital pharmacy education in Europe will represent an agreement on the competencies, knowledge, skills and attitudes required by the profession in order to deliver the 44 European Statements of Hospital Pharmacy. These statements represent a vision for hospital pharmacy practice development in all countries for the purpose of improving patient care.
The consultation on the framework’s initial content will be conducted according to Delphi principles. The online portal will enable contributors to participate anonymously and continuously, as well as be informed by the ongoing contributions of others. Consecutive rounds of consultation, facilitated by an independent moderator team, will aim to achieve a consensus on the content in time to be voted on at the EAHP annual General Assembly in Malta in June 2017.
The registration portal for the consultation will close on 31 January 2017, with the first round of consultation commencing in February 2018.
Joan Peppard, EAHP President, remarked:
“Transparency and wide consultation are fundamental to the common training framework. In the process of finalising the content of a common training framework for hospital pharmacy we want to ensure all perspectives are drawn upon in order to enrich the outcome. The perspectives we are searching for include those from different national health systems, the various healthcare professionals that hospital pharmacists work with, system managers, education providers, other branches of pharmacy, and, of course, the patients we serve. The more we collaborate in the process of creation, the stronger the result will be. On behalf of hospital pharmacy, I want to convey encouragement to ALL interested individuals and organisations to register to participate today!“
The registration portal for the CTF consultation is available HERE
The European Centre for Disease Control and Prevention has published its latest EU-wide data on antibiotic resistance and antibiotic consumption. In 2015, antibiotic resistance continued to increase for most bacteria and antibiotics under surveillance.
In particular, the EU average percentage of carbapenem resistance in Klebsiella pneumoniae increased from 6.2% in 2012 to 8.1% in 2015, and combined resistance to carbapenems and polymyxins (e.g. colistin) was sometimes reported. These two groups of antibiotics are considered last-line antibiotics as they usually are the last treatment options for patients infected with bacteria resistant to other available antibiotics.
While antibiotic consumption in hospitals significantly increased in several EU Member States, antibiotic consumption in the community decreased in six EU Member States.
ECDC Acting Director, Dr Andrea Ammon, said: “Antibiotic resistance in Klebsiella pneumoniae is of increasing concern in Europe. More than one third of the isolates reported to ECDC for 2015 were resistant to at least one of the antibiotic groups under surveillance, and combined resistance to multiple antibiotic groups was common. Moreover, the emergence of K. pneumoniae infections with combined resistance to carbapenems and colistin is worrisome and an important warning that options for treatment are now even more limited than in the past“.
Dr Ammon added: “However, the decrease of antibiotic consumption in the community in six countries is a positive sign and shows that we are starting to use antibiotics more prudently. Prudent use of antibiotics is pivotal, both in the community and in hospitals, to ensure that these drugs remain effective“.
ECDC’s data also show that antibiotic resistance in Escherichia coli, one of the most frequent causes of bloodstream infections and community- and healthcare-associated urinary tract infections, requires close attention as the percentages of isolates resistant to commonly used antibiotics continues to increase throughout Europe. In contrast, the percentage of meticillin-resistant Staphylococcus aureus (MRSA) showed a significantly decreasing trend at EU/EEA level between 2012 and 2015. Despite this positive development, MRSA remains a public health priority as eight out of thirty countries reported percentages above 25%.
More information HERE
The European Commission is inviting stakeholders to provide comment on how prevailing EU regulations related to paediatric medicine development might be improved. The deadline for comments is 20th February 2017.
2017 will mark ten years since the coming into being of the 2007 Paediatric Regulation. This piece of EU law aimed to improve the regulatory environment for paediatric medicine development by increasing obligations upon companies to include ‘paediatric investigation plans‘ within their processes for conducting research on potential new medicines. These tougher obligations are also complimented by incentives for paediatric research such as extended market exclusivity and free scientific advice.
The document accompanying the consultation acknowledges that the 2007 Paediatric Regulation undoubtedly improved attention on paediatric development, with nearly 1,000 paediatric investigation plans agreed as a result. However, other areas of the regulation may not have been so successful in their intent.
A series of 17 prompting questions aims to draw out from stakeholders their experiences of the regulation, and suggestions for improvement. More information HERE
The online first edition of the European Journal of Hospital Pharmacy (EJHP) has published a new case report examining experience of intrathecal hydroxypropyl-β-cyclodextrin therapy for a child with Niemann-Pick disease type C.
More information HERE
